Induction of A3A in non-small cell lung cancer (NSCLC) cells treated with receptor tyrosine kinase inhibitors (TKIs) promotes genomic instability and the development of drug resistance that contributes to disease relapse [11–13]. Here, NTRK1 is linked to non-small cell lung carcinoma.